These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 20682979

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ.
    Biochem Biophys Res Commun; 2005 Feb 04; 327(1):225-33. PubMed ID: 15629453
    [Abstract] [Full Text] [Related]

  • 4. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.
    Int J Oncol; 2008 Dec 04; 33(6):1257-62. PubMed ID: 19020759
    [Abstract] [Full Text] [Related]

  • 5. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, Miwa H.
    Anticancer Res; 2008 Dec 04; 28(4B):2087-92. PubMed ID: 18751380
    [Abstract] [Full Text] [Related]

  • 6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 Sep 04; 63(8):553-60. PubMed ID: 18571892
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
    Shang XB, Yu ZT, Tang P, Zhang XZ.
    Zhonghua Yi Xue Za Zhi; 2008 Oct 28; 88(39):2799-802. PubMed ID: 19080461
    [Abstract] [Full Text] [Related]

  • 9. Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells.
    Wang Z, Liang X, Cheng Z, Xu Y, Yin P, Zhu H, Li Q, Qian X, Liu J.
    Anticancer Drugs; 2013 Apr 28; 24(4):355-65. PubMed ID: 23426174
    [Abstract] [Full Text] [Related]

  • 10. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug 28; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK.
    Anticancer Res; 2011 Nov 28; 31(11):3843-9. PubMed ID: 22110208
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb 28; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 14. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.
    Clin Cancer Res; 2005 Sep 01; 11(17):6212-7. PubMed ID: 16144923
    [Abstract] [Full Text] [Related]

  • 15. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.
    van Huis-Tanja LH, Kweekel DM, Lu X, Franken K, Koopman M, Gelderblom H, Antonini NF, Punt CJ, Guchelaar HJ, van der Straaten T.
    Mutat Res; 2014 Jan 01; 759():37-44. PubMed ID: 24220697
    [Abstract] [Full Text] [Related]

  • 16. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW, Wen F.
    Oncol Rep; 2011 Mar 01; 25(3):781-8. PubMed ID: 21165580
    [Abstract] [Full Text] [Related]

  • 17. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.
    Mol Pharmacol; 2011 Jul 01; 80(1):136-46. PubMed ID: 21493726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
    Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y, Wang X.
    Mol Med Rep; 2014 Jun 01; 9(6):2423-8. PubMed ID: 24699918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.